使用加速度计对帕金森病患者的MDS-UPDRS-III震测量的术后量化
Annemarie Smid1,2, Jan Willem J Elting3,4, Teus van Laar3,4
1Department of Neurosurgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1 HPC AB71, 9713 GZ, Groningen, The Netherlands. a.smid01@umcg.nl.
Journal of neural transmission (Vienna, Austria : 1996)
|March 11, 2026
概括
客观加速度计准确地测量了帕金森病 (PD) 的震,与运动障碍学会统一的PD评级表 (MDS-UPDRS) 相对应得很好. 这项技术提供了一个可靠的,客观的工具来补充临床震评估.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 的震评估依赖于主观的运动障碍学会统一的PD评级表 (MDS-UPDRS).
- 在MDS-UPDRS得分中的主观性和评级者依赖性限制了客观评价.
- 加速度计为客观震动量化提供了一个潜在的解决方案.
研究的目的:
- 根据MDS-UPDRS标准,开发和验证一种加速计算法,用于测量和分类PD患者的手震.
- 评估客观加速度测量测量和主观MDS-UPDRS震荡得分之间的一致性.
- 评估加速度计在补充临床PD震评估中的可靠性和潜力.
主要方法:
- 64名PD患者和64名匹配的对照在停药状态下接受了食指3D加速计.
- 两个评级人员使用MDS-UPDRS标准评估震.
- 分析涉及比较加速度计数据 (振幅,功率在4-7赫兹范围内) 与使用科恩的卡帕和相关系数的MDS-UPDRS得分.
主要成果:
- 拟议的加速度计算法显示与MDS-UPDRS震振幅等级的基本一致 (>80.2%, κ ≥ 0.732).
- 加速计测量结果显示,测试重复测试的可靠性很好或很好 (ICC ≥ 0.789).
- 在休息震 (CRT) 的加速度计常数测量和MDS-UPDRS评级之间发现了差异,相关性较低 (R2 < 0.469).
结论:
- MDS-UPDRS震动评估可以可靠地转化为客观的加速度计测量.
- 加速度计提供了一个有希望的,客观的方法来减少PD震评估中的评分器变化.
- 虽然CRT测量显示出差异,但加速度计可以作为视觉评估的宝贵补充,用于在临床环境中客观地监测震.
相关概念视频
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K


